Cargando…

Nucleocapsid as a next-generation COVID-19 vaccine candidate

Multiple new variants of the SARS-CoV-2 virus have emerged globally, due to viral mutation. The majority of COVID-19 vaccines contain SARS-CoV-2 spike protein, which is susceptible to mutation. It is known that protection against COVID-19 after two doses of mRNA vaccine continuously wanes over time....

Descripción completa

Detalles Bibliográficos
Autores principales: Oronsky, Bryan, Larson, Christopher, Caroen, Scott, Hedjran, Farah, Sanchez, Ana, Prokopenko, Elena, Reid, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250828/
https://www.ncbi.nlm.nih.gov/pubmed/35788417
http://dx.doi.org/10.1016/j.ijid.2022.06.046
_version_ 1784739886322941952
author Oronsky, Bryan
Larson, Christopher
Caroen, Scott
Hedjran, Farah
Sanchez, Ana
Prokopenko, Elena
Reid, Tony
author_facet Oronsky, Bryan
Larson, Christopher
Caroen, Scott
Hedjran, Farah
Sanchez, Ana
Prokopenko, Elena
Reid, Tony
author_sort Oronsky, Bryan
collection PubMed
description Multiple new variants of the SARS-CoV-2 virus have emerged globally, due to viral mutation. The majority of COVID-19 vaccines contain SARS-CoV-2 spike protein, which is susceptible to mutation. It is known that protection against COVID-19 after two doses of mRNA vaccine continuously wanes over time. If viral variants contain mutated spike protein, current vaccines may not provide robust protection. This perspective suggests the inclusion of SARS-CoV-2 nucleocapsid protein in future COVID-19 vaccines and boosters, as nucleocapsid is much less vulnerable to mutation and may provide stronger immunity to novel viral variants.
format Online
Article
Text
id pubmed-9250828
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-92508282022-07-05 Nucleocapsid as a next-generation COVID-19 vaccine candidate Oronsky, Bryan Larson, Christopher Caroen, Scott Hedjran, Farah Sanchez, Ana Prokopenko, Elena Reid, Tony Int J Infect Dis Perspective Multiple new variants of the SARS-CoV-2 virus have emerged globally, due to viral mutation. The majority of COVID-19 vaccines contain SARS-CoV-2 spike protein, which is susceptible to mutation. It is known that protection against COVID-19 after two doses of mRNA vaccine continuously wanes over time. If viral variants contain mutated spike protein, current vaccines may not provide robust protection. This perspective suggests the inclusion of SARS-CoV-2 nucleocapsid protein in future COVID-19 vaccines and boosters, as nucleocapsid is much less vulnerable to mutation and may provide stronger immunity to novel viral variants. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022-09 2022-07-03 /pmc/articles/PMC9250828/ /pubmed/35788417 http://dx.doi.org/10.1016/j.ijid.2022.06.046 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Perspective
Oronsky, Bryan
Larson, Christopher
Caroen, Scott
Hedjran, Farah
Sanchez, Ana
Prokopenko, Elena
Reid, Tony
Nucleocapsid as a next-generation COVID-19 vaccine candidate
title Nucleocapsid as a next-generation COVID-19 vaccine candidate
title_full Nucleocapsid as a next-generation COVID-19 vaccine candidate
title_fullStr Nucleocapsid as a next-generation COVID-19 vaccine candidate
title_full_unstemmed Nucleocapsid as a next-generation COVID-19 vaccine candidate
title_short Nucleocapsid as a next-generation COVID-19 vaccine candidate
title_sort nucleocapsid as a next-generation covid-19 vaccine candidate
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250828/
https://www.ncbi.nlm.nih.gov/pubmed/35788417
http://dx.doi.org/10.1016/j.ijid.2022.06.046
work_keys_str_mv AT oronskybryan nucleocapsidasanextgenerationcovid19vaccinecandidate
AT larsonchristopher nucleocapsidasanextgenerationcovid19vaccinecandidate
AT caroenscott nucleocapsidasanextgenerationcovid19vaccinecandidate
AT hedjranfarah nucleocapsidasanextgenerationcovid19vaccinecandidate
AT sanchezana nucleocapsidasanextgenerationcovid19vaccinecandidate
AT prokopenkoelena nucleocapsidasanextgenerationcovid19vaccinecandidate
AT reidtony nucleocapsidasanextgenerationcovid19vaccinecandidate